For the Inventor, By the Inventor

Enter assignee name

Hayward, CA, United States of America

Aradigm Corporation

USPTO Granted Patents = 130

% Expired Patents = 30.8

CIPO Patents = 3

EPO Patents = 4

Trademarks = 3

Forward Citations = 9,830

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Reid M Rubsamen (67 out of 75 patents)

Igor Gonda (44 out of 54 patents)

Jeffrey A Schuster (30 out of 43 patents)

4. Lester John Lloyd (23 out of 49 patents)

5. Stephen J Farr (20 out of 32 patents)

6. Peter M Lloyd (17 out of 18 patents)

7. David C Cipolla (16 out of 21 patents)

8. James Blanchard (13 out of 15 patents)

9. Sudarsan Srinivasan (12 out of 12 patents)

10. Rajesh S Patel (12 out of 28 patents)

11. Eric T Johansson (10 out of 28 patents)

12. Carl Ritson (8 out of 29 patents)

13. Christopher J Flaim (6 out of 8 patents)

14. David E Goodman (5 out of 16 patents)

15. Thor Miller Wilbanks (3 out of 6 patents)

Core Competencies:

Aerosol Drug Delivery

Ciprofloxacin Formulation

Liposomal Formulations

Inhaled Insulin

Smoking Cessation

Nanocrystals

Pulmonary Delivery

Temperature Control

Non-destructive Analysis

Drug Nanocrystals

Tobacco Use

Porous Membrane

130 patents: Sort by Forward Citations

1. 10420765 - Concentrated, inhalable ciprofloxacin formulation (2019-09-24),

2. 10376508 - Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria (2019-08-13),

3. 9987227 - Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile (2018-06-05),

4. 9968555 - Liposomal formulations that form drug nanocrystals after freeze-thaw (2018-05-15),

5. 9857387 - Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals (2018-01-02),

6. 9844548 - Liposomal ciprofloxacin formulations with encapsulated ciprofloxacin nanocrystals (2017-12-19),

7. 9592220 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract (2017-03-14),

8. 9545401 - Concentrated, inhalable ciprofloxacin formulation (2017-01-17),

9. 9532986 - Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria (2017-01-03),

10. 9511199 - Pore structures for reduced pressure aerosolization (2016-12-06),

11. 9457006 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract (2016-10-04),

12. 9421185 - Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract (2016-08-23),

13. 9372198 - Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals (2016-06-21),

14. 9259424 - Concentrated, inhalable antibiotic formulation (2016-02-16),

15. 9078897 - Concentrated, inhalable antibiotic formulation (2015-07-14),

Aradigm Corporation, based in Hayward, California, specializes in the development of innovative aerosol drug delivery systems. The company focuses on advanced formulations, including ciprofloxacin and liposomal formulations, aimed at enhancing pulmonary delivery for various therapeutic applications. Aradigm is also engaged in research related to inhaled insulin, smoking cessation solutions, and the use of nanocrystals, emphasizing temperature control in drug delivery. Their technologies aim to improve patient outcomes through effective respiratory therapies.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Aradigm Corporation

130 Patents

#1 in Hayward, CA

#668 in California

#2,977 in US

#6,175 in the World

Hayward, CA, United States of America

Aradigm Corporation

Forward Citations = 9,830

42 inventors:

Reid M Rubsamen (67 out of 75 patents)

Igor Gonda (44 out of 54 patents)

Jeffrey A Schuster (30 out of 43 patents)

4. Lester John Lloyd (23 out of 49 patents)

5. Stephen J Farr (20 out of 32 patents)

Please report any incorrect information to [email protected]

Loading…